Copyright
©2010 Baishideng.
World J Gastroenterol. Mar 7, 2010; 16(9): 1093-1096
Published online Mar 7, 2010. doi: 10.3748/wjg.v16.i9.1093
Published online Mar 7, 2010. doi: 10.3748/wjg.v16.i9.1093
Table 1 Demographic, virological, immunologic characteristics, and outcomes of HIV and HBV co-infected patients in 2 groups according to HBsAg status
Persistent HBsAg | Loss of HBsAg | P | |
Number of patients (%) | 205 (90.7) | 21 (9.3) | |
Median age (IQR) | 46 (42-51) | 41 (33-55) | 0.305 |
Gender (%) | 0.353 | ||
Female | 32 (15.6) | 5 (23.8) | |
Male | 173 (84.4) | 16 (76.2) | |
Ethnicity (%) | |||
White | 25 (12.2) | 3 (14.3) | 0.731 |
Hispanic | 42 (20.5) | 6 (28.6) | 9.404 |
Black | 134 (65.4) | 12 (57.1) | 0.453 |
Other | 4 (2.0) | 0 (0.0) | |
HIV risk factor (%) | |||
Hetero | 59 (28.8) | 5 (23.8) | 0.630 |
MSM | 81 (39.5) | 12 (57.1) | 0.118 |
IDU | 27 (13.2) | 3 (14.3) | 0.747 |
IDU and hetero | 10 (4.9) | 0 (0.0) | |
IDU and MSM | 6 (2.9) | 0 (0.0) | |
Other | 5 (2.4) | 0 (0.0) | |
Unknown | 17 (8.3) | 1 (4.8) | 1.000 |
HCV co-infection (%) | 0.789 | ||
HCV positive | 49 (23.9) | 4 (19.0) | |
HAART (%) | 0.746 | ||
No HAART | 30 (14.6) | 2 (9.5) | |
HAART | 175 (85.4) | 19 (90.5) | |
ALT baseline | 0.469 | ||
Median ALT baseline (IQR) | 44.50 (26.00-79.00) | 24.50 (17.50-100.50) | |
CD4 baseline | |||
Median CD4 baseline (IQR) | 270 (115-439) | 271 (63-594) | 0.449 |
CD4 baseline > 500 (%) | 25 (12.2) | 5 (23.8) | 0.078 |
HIV viral load baseline | |||
Median HIV VL (log) (IQR) | 4.47 (3.01-5.45) | 4.03 (2.70-5.39) | 0.841 |
HIV VL ≤ 400 (%) | 40 (19.5) | 3 (14.3) | 0.763 |
Table 2 Univariate analysis of factors associated with loss of HBsAg
P | |
ALT baseline | 0.737 |
HCV co-infection | 0.660 |
HIV VL baseline | 0.981 |
HIV VL end of follow-up | 0.790 |
CD4 cell counts baseline | 0.052 |
CD4 cell count end of follow-up | 0.064 |
CD4 cell count gain | 0.118 |
HAART | 0.764 |
Table 3 Multivariate Cox regression analysis of factors associated with loss of HBsAg
Odds ratio (95% CI) | P | |
ALT baseline | ||
Normal ALT (ref) | ||
Elevated ALT | 0.157 (0.013-1.829) | 0.139 |
HCV co-infection | ||
HCV negative (ref) | ||
HCV positive | 0.073 (0.002-2.802) | 0.160 |
HIV VL baseline (copies/mL) | ||
HIV VL ≤ 75 | 3.018 (0.028-325.768) | 0.644 |
HIV VL 76-500 | 9.195 (0.037-2289.798) | 0.431 |
HIV VL 501-100 000 | 1.026 (0.009-118.554) | 0.991 |
HIV VL > 100 000 (ref) | ||
HIV VL end of follow up (copies/mL) | ||
HIV VL ≤ 75 | 1134.708 (0.000-1.43E+151) | 0.968 |
HIV VL 76-500 | 4403. 835 (0.000-5.55E+151) | 0.962 |
HIV VL 501-100 000 | 3338.767 (0.000-4.19E+151) | 0.963 |
HIV VL > 100 000 (ref) | ||
CD4 baseline (cells/mm3) | ||
CD4 < 200 (ref) | ||
CD4 200-350 | 0.983 (0.042-22.809) | 0.992 |
CD4 351-500 | 0.000 (0.000-1.35E+034) | 0.834 |
CD4 > 500 | 76.174 (2.233-2598.481) | 0.016 |
CD4 end of follow-up (cells/mm3) | ||
CD4 < 200 (ref) | ||
CD4 200-350 | 9.113 (0.141-587.310) | 0.299 |
CD4 351-500 | 0.521 (0.018-15.301) | 0.705 |
CD4 > 500 | 0.003 (0.000-0.631) | 0.034 |
CD4 gain (cells/mm3) | ||
CD4 gain ≤ 150 (ref) | ||
CD4 gain > 150 | 2.800 (0.122-64.365) | 0.520 |
HAART | ||
No HAART (ref) | ||
HAART | 0.117 (0.004-3.105) | 0.199 |
- Citation: Jr GP, Kim JH, Suh JS, Sharp VL. Predictors of loss of hepatitis B surface antigen in HIV-infected patients. World J Gastroenterol 2010; 16(9): 1093-1096
- URL: https://www.wjgnet.com/1007-9327/full/v16/i9/1093.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i9.1093